U.S. markets closed

FibroGen, Inc. (FGEN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
40.02-1.31 (-3.17%)
At close: 4:00PM EST

40.02 0.00 (0.00%)
After hours: 4:01PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close41.33
Open41.33
Bid40.00 x 1000
Ask40.03 x 800
Day's Range39.84 - 41.38
52 Week Range22.65 - 51.56
Volume368,750
Avg. Volume738,524
Market Cap3.642B
Beta (5Y Monthly)1.70
PE Ratio (TTM)N/A
EPS (TTM)-2.57
Earnings DateNov 04, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est62.13
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • FibroGen, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates
    Simply Wall St.

    FibroGen, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates

    Investors in FibroGen, Inc. (NASDAQ:FGEN) had a good week, as its shares rose 7.6% to close at US$41.28 following the...

  • FibroGen Inc (FGEN) Q3 2020 Earnings Call Transcript
    Motley Fool

    FibroGen Inc (FGEN) Q3 2020 Earnings Call Transcript

    Ladies and gentlemen, thank you for standing by, and welcome to the FibroGen Third Quarter 2020 Financial Results Conference Call. Joining me on today's call are Enrique Conterno, our Chief Executive Officer; Dr. Percy Carter, our Chief Scientific Officer; Pat Cotroneo, our Chief Financial Officer; Thane Wettig, our Chief Commercial Officer; Dr. Peony Yu, our Chief Medical Officer; Chris Chung, our Senior Vice President of China Operations; and Dr. Elias Kouchakji, our Senior Vice President of Clinical Development, Drug Safety and Pharmaco Vigilance.

  • FibroGen to Present at Upcoming Investor Conferences
    GlobeNewswire

    FibroGen to Present at Upcoming Investor Conferences

    SAN FRANCISCO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following healthcare conferences: * Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, 2020 at 1:20 PM Eastern Time * Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020 at 12:35 PM Eastern TimeA live audio webcast will be available on the “Events & Presentations” section of the FibroGen Investor webpage at https://fibrogen.gcs-web.com/. A replay will be available for approximately 30 days.About FibroGenFibroGen, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines to treat unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia. Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), Duchenne muscular dystrophy (DMD), and coronavirus (COVID-19). For more information, please visit www.fibrogen.com.Contact: FibroGen, Inc.Investors: Michael Tung, M.D. Corporate Strategy / Investor Relations 1.415.630.0131 mtung@fibrogen.comMedia: Jennifer Harrington +1.610.574.9196 Jennifer.Harrington@gcihealth.com